Advances in chemotherapy for HER2-negative metastatic breast cancer

被引：3
作者：
Mukai, Hirofumi [1 ]
Ito, Mayuko [1 ]
机构：
[1] Natl Canc Ctr Hosp East, Dept Breast & Med Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba, Japan
来源：
CHINESE CLINICAL ONCOLOGY | 2018年 / 7卷 / 03期
关键词：
Breast cancer; chemotherapy; quality of life (QOL); survival;
D O I：
10.21037/cco.2018.06.01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Metastatic breast cancer cannot be curable, but significant improvement in overall survival has been observed with the appearance of new agents. The purpose of treatment is to prolong survival and to improve quality of life by reducing cancer-related symptoms. To achieve these goals, individualized approach is required. Chemotherapy is used for patients with hormone receptor negative breast cancer or hormone receptor positive patients who have cancer-related symptoms. The choice of regimen (single-agent or a combination), selection of a specific therapy and the duration of treatment depend on multiple factors, including the tumor burden, general health status, prior treatments and toxicities, and patient preferences.
引用
收藏
页数：5
相关论文
共 19 条
  • [1] Alagizy H A, 2015, Hematol Oncol Stem Cell Ther, V8, P22, DOI 10.1016/j.hemonc.2014.11.003
  • [2] High-Dose Chemotherapy With Autologous Hematopoietic Stem-Cell Transplantation in Metastatic Breast Cancer: Overview of Six Randomized Trials
    Berry, Donald A.
    Ueno, Naoto T.
    Johnson, Marcella M.
    Lei, Xiudong
    Caputo, Jean
    Smith, Dori A.
    Yancey, Linda J.
    Crump, Michael
    Stadtmauer, Edward A.
    Biron, Pierre
    Crown, John P.
    Schmid, Peter
    Lotz, Jean-Pierre
    Rosti, Giovanni
    Bregni, Marco
    Demirer, Taner
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (24) : 3224 - 3231
  • [3] Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
    Byrski, Tomasz
    Dent, Rebecca
    Blecharz, Pawel
    Foszczynska-Kloda, Malgorzata
    Gronwald, Jacek
    Huzarski, Tomasz
    Cybulski, Cezary
    Marczyk, Elzbieta
    Chrzan, Robert
    Eisen, Andrea
    Lubinski, Jan
    Narod, Steven A.
    [J]. BREAST CANCER RESEARCH, 2012, 14 (04):
  • [4] 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
    Cardoso, F.
    Costa, A.
    Senkus, E.
    Aapro, M.
    Andre, F.
    Barrios, C. H.
    Bergh, J.
    Bhattacharyya, G.
    Biganzoli, L.
    Cardoso, M. J.
    Carey, L.
    Corneliussen-James, D.
    Curigliano, G.
    Dieras, V.
    El Saghir, N.
    Eniu, A.
    Fallowfield, L.
    Fenech, D.
    Francis, P.
    Gelmon, K.
    Gennari, A.
    Harbeck, N.
    Hudis, C.
    Kaufman, B.
    Krop, I.
    Mayer, M.
    Meijer, H.
    Mertz, S.
    Ohno, S.
    Pagani, O.
    Papadopoulos, E.
    Peccatori, F.
    Penault-Llorca, F.
    Piccart, M. J.
    Pierga, J. Y.
    Rugo, H.
    Shockney, L.
    Sledge, G.
    Swain, S.
    Thomssen, C.
    Tutt, A.
    Vorobiof, D.
    Xu, B.
    Norton, L.
    Winer, E.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (01) : 16 - 33
  • [5] Single agent versus combination chemotherapy for metastatic breast cancer
    Carrick, Sue
    Parker, Sharon
    Thornton, Charlene E.
    Ghersi, Davina
    Simes, John
    Wilcken, Nicholas
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2009, (02):
  • [6] The impact of new chemotherapeutic and agents on survival in a population-based of women with metastatic breast cancer hormone cohort
    Chia, Stephen K.
    Speers, Caroline H.
    D'yachkova, Yulia
    Kang, Anna
    Malfair-Taylor, Suzanne
    Barnett, Jeff
    Coldman, Andy
    Gelmon, Karen A.
    O'Reilly, Susan E.
    Olivotto, Ivo A.
    [J]. CANCER, 2007, 110 (05) : 973 - 979
  • [7] Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00
    Colleoni, Marco
    Gray, Kathryn P.
    Gelber, Shari
    Lang, Istvan
    Thurlimann, Beat
    Gianni, Lorenzo
    Abdi, Ehtesham A.
    Gomez, Henry L.
    Linderholm, Barbro K.
    Puglisi, Fabio
    Tondini, Carlo
    Kralidis, Elena
    Eniu, Alexandru
    Cagossi, Katia
    Rauch, Daniel
    Chirgwin, Jacquie
    Gelber, Richard D.
    Regan, Meredith M.
    Coates, Alan S.
    Price, Karen N.
    Viale, Giuseppe
    Goldhirsch, Aron
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) : 3400 - +
  • [8] Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women
    Fossati, R
    Confalonieri, C
    Torri, V
    Ghislandi, E
    Penna, A
    Pistotti, V
    Tinazzi, A
    Liberati, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (10) : 3439 - 3460
  • [9] Survival of metastatic breast carcinoma patients over a 20-year period - A retrospective analysis based on individual patient data from six consecutive studies
    Gennari, A
    Conte, P
    Rosso, R
    Orlandini, CA
    Bruzzi, P
    [J]. CANCER, 2005, 104 (08) : 1742 - 1750
  • [10] Duration of Chemotherapy for Metastatic Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
    Gennari, Alessandra
    Stockler, Martin
    Puntoni, Matteo
    Sormani, Mariapia
    Nanni, Oriana
    Amadori, Dino
    Wilcken, Nicholas
    D'Amico, Mauro
    DeCensi, Andrea
    Bruzzi, Paolo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2144 - 2149
12